Shopping Cart
- Remove All
- Your shopping cart is currently empty
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,270 | 10-14 weeks | |
50 mg | $2,980 | 10-14 weeks | |
100 mg | $4,000 | 10-14 weeks |
Description | LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. |
Molecular Weight | 448.44 |
Formula | C21H23F3N6O2 |
Cas No. | 1998714-25-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.